The ModifiedGlasgow Prognostic Score and Survival in Colorectal Cancer: A Pooled Analysis of the Literature

Author(s): Fausto Petrelli, Sandro Barni, Andrea Coinu, Paola Bertocchi, Karen Borgonovo, Mary Cabiddu, Mara Ghilardi, Alberto Zaniboni

Journal Name: Reviews on Recent Clinical Trials

Volume 10 , Issue 2 , 2015

Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Background: It has been reported that the combination of inflammation parameters, such as albumin and C-reactive protein, in the modified Glasgow prognostic score (m-GPS) is a poor prognostic indicator in several malignancies. Here, we quantify the prognostic impact of this score and assess its value in colorectal cancer.

Methods: A systematic review of electronic databases was conducted to identify publications exploring the association of m-GPS with outcome in colorectal cancer. Overall survival (OS) was the primary outcome, and cancer-specific survival (CSS), progression-free survival, and disease-free survival were secondary outcomes. Data from studies reporting a hazard ratio (HR) and 95% confidence interval (CI) were included in a metaanalysis. Pooled HRs were computed and weighted using generic inverse-variance and random effects modeling. All statistical tests were two-sided.

Results: Nine studies, which included a total of 2,227 patients, were included in the analysis. Overall, according to multivariate analysis, m-GPS ≥1 was independently associated with an HR for OS of 1.69 (95% CI=1.4–2.04; P<0.00001), an effect observed in all stages of disease. Six studies including a total of 1,751 patients reported HR for CSS. Overall, a high m-GPS was associated with an HR for CSS of 1.84 (95% CI=1.43–2.37; P<0.00001).

Conclusions: A high m-GPS is associated with poor OS in colorectal cancer. The m-GPS is a cheap and easily evaluable biomarker, and its incorporation into known prognostic scores for clinical decision making warrants further investigation in this setting.

Keywords: Glasgow prognostic score, albumin, C-reactive protein, colorectal cancer, prognosis.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2015
Published on: 13 July, 2015
Page: [135 - 141]
Pages: 7
DOI: 10.2174/1574887110666150317121413
Price: $65

Article Metrics

PDF: 39